Cargando…

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis

AIMS: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are the recommended first injectable therapy in type 2 diabetes. However, long‐term persistence is suboptimal and partly attributable to gastrointestinal tolerability, particularly during initiation/escalation. Gradual titration of fixed‐ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rayner, Christopher K., Wu, Tongzhi, Aroda, Vanita R., Whittington, Craig, Kanters, Steve, Guyot, Patricia, Shaunik, Alka, Horowitz, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756611/ https://www.ncbi.nlm.nih.gov/pubmed/32991041 http://dx.doi.org/10.1111/dom.14202

Ejemplares similares

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences
por: Horowitz, Michael, et al.
Publicado: (2017)

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
por: Trujillo, Jennifer M., et al.
Publicado: (2018)

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
por: Frias, Juan P., et al.
Publicado: (2018)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial
por: Wysham, Carol, et al.
Publicado: (2017)

Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2018)

More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L
por: Frias, Juan, et al.
Publicado: (2018)

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
por: Aroda, Vanita R., et al.
Publicado: (2017)

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world
por: Dailey, George, et al.
Publicado: (2019)

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
por: Davies, Melanie J., et al.
Publicado: (2017)

iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
por: Hinnen, Debbie, et al.
Publicado: (2018)

Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes
por: Kis, János Tibor, et al.
Publicado: (2021)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study
por: Candido, Riccardo, et al.
Publicado: (2022)

Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
por: Haluzík, Martin, et al.
Publicado: (2020)

Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying
por: Marathe, Chinmay S., et al.
Publicado: (2022)

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
por: Rosenstock, Julio, et al.
Publicado: (2017)

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
por: Shaefer, Charles F.
Publicado: (2016)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
por: Aroda, Vanita R., et al.
Publicado: (2018)

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
por: Tabák, Ádám G., et al.
Publicado: (2019)

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials
por: Davidson, J. A., et al.
Publicado: (2019)

Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution
por: Jalleh, Ryan, et al.
Publicado: (2020)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial
por: Inoue, Megumi, et al.
Publicado: (2019)

Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)
por: Bala, Cornelia, et al.
Publicado: (2022)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study
por: Qin, Lei, et al.
Publicado: (2017)

Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
por: Borg, Malcolm J., et al.
Publicado: (2020)

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin
por: Seino, Y, et al.
Publicado: (2014)

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
por: Blonde, Lawrence, et al.
Publicado: (2020)

Glucagon‐like peptide‐1 receptor agonists, weight loss, and gastric emptying: have I gut news for you
por: Jalleh, Ryan J., et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
por: Qin, Lei, et al.
Publicado: (2017)

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial
por: Iizuka, Katsumi, et al.
Publicado: (2021)

Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans
por: Wu, Tongzhi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6d69jkgsi0hpkpnesm295qnvl7